Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic modalities in hepatitis C: challenges and development.

R Moreno-Otero1

  • 1Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain. rmoreno.hlpr@salud.madrid.org

Journal of Viral Hepatitis
|January 19, 2005
PubMed
Summary

Predicting Hepatitis C Virus (HCV) treatment response involves patient factors and viral characteristics. Pegylated interferon plus ribavirin is the standard of care for chronic HCV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.

Genes and immunity·2015
Same author

Letter: impact of mild alcohol consumption in chronic hepatitis C treatment.

Alimentary pharmacology & therapeutics·2013
Same author

Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.

Genes and immunity·2013
Same author

Letter: acute hepatitis B - to treat or not to treat?

Alimentary pharmacology & therapeutics·2012
Same author

Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.

Alimentary pharmacology & therapeutics·2012
Same author

Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial.

Scandinavian journal of gastroenterology·2012

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) pathogenicity is poorly understood due to limited animal models and slow disease progression.
  • Challenges in HCV research include a narrow host range and protracted liver disease onset.
  • Predictive factors for treatment response in chronic HCV infection have been identified.

Purpose of the Study:

  • To review current understanding of Hepatitis C Virus (HCV) pathogenicity.
  • To identify patient and viral characteristics that predict treatment response.
  • To discuss the evolution and efficacy of interferon-based therapies for chronic HCV.

Main Methods:

  • Review of existing literature on HCV infection and treatment.
  • Analysis of patient and viral factors influencing treatment outcomes.

Related Experiment Videos

  • Comparison of conventional interferon-alpha with pegylated interferon formulations.

    • Main Results:

    • Patient factors (viral load, genotype, body weight, age, liver histology, HIV co-infection, adherence) and viral characteristics predict treatment response.
    • Pegylated interferons (pegIFN-alpha-2a and pegIFN-alpha-2b) offer improved pharmacokinetics (longer half-life, reduced clearance) over conventional interferon-alpha.
    • Combination therapy with pegylated interferon and ribavirin significantly increases sustained virological response rates.

    Conclusions:

    • Pegylated interferon combined with ribavirin is the current standard of care for chronic Hepatitis C.
    • Understanding predictive factors is crucial for optimizing HCV treatment strategies.
    • Advancements in interferon therapy have improved outcomes for patients with chronic HCV infection.